Pharmaceutical company Wockhardt on Friday announced that the company has entered into an agreement with Enso Healthcare DMCC (Enso), a company incorporated in Dubai, UAE and Human Vaccine LLC (HV), a wholly owned subsidiary of the sovereign wealth fund of the Russian Federation (RDIF), for the manufacture and supply of the Sputnik V/Sputnik Light vaccine against Covid-19.
‘’Subject to requisite approvals and other conditions, upon successful technology transfer from HV to the company, the company will manufacture and supply to Enso up to 620 million doses of the Sputnik V vaccine and the Sputnik Light vaccine against Covid-19,” Wockhardt said in a statement.
The agreement between the Company, HV, Enso was reached under the aegis of Enso, RDIF’s coordinating partner for sourcing Sputnik vaccine in India.
Recent Posts
Experts Warn of Global Threat from Chronic Wasting Disease
Chronic Wasting Disease (CWD) is a highly contagious and fatal neurological disorder that affects deer,…
CDC Reschedules Vaccine Advisory Meeting to April 15-16
The Centers for Disease Control and Prevention (CDC) has announced a rescheduling of its vaccine…
India’s Specialty Chemicals Rebound, Pharma Exports Surge
India’s specialty chemicals industry and pharmaceutical exports continue to showcase resilience amid global uncertainties. As…
Gut Bacteria: The Hidden Key to Human Brain Evolution
The evolution of the human brain is one of the most fascinating topics in science.…
Obesity and Sleep Apnea: Warning Signs and Prevention Tips
Sleep apnea is a common yet serious sleep disorder that affects millions of people worldwide.…
Harmful Bacteria in the Human Body: Risks and Prevention
The human body is home to trillions of bacteria, many of which are beneficial for…